Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Comorbidities and Medications in Huntington’s Disease, Parkinson’s Disease and the General Population in a US Claims Database
Movement Disorders
P6 - Poster Session 6 (12:00 PM-1:00 PM)
3-011
Truven MarketScan has been previously used to explore healthcare utilisation and direct medical costs among HD patients by stages of disease. US claims data can offer insights on the natural history of HD and real-world standard practices.
To characterise comorbidities, symptoms and treatment patterns of patients with Huntington’s disease (HD) versus patients with Parkinson’s disease (PD) versus the general population (GP) excluding neurodegenerative diseases.
Patients were matched by age, gender, database type (Commercial/Medicaid) and enrolment in a database prior to the index date (1st January 2017). The selected diseases and medications were related to HD and its symptoms, psychiatric comorbidities, common diseases and commonly used medications. Comorbidities were reported by International Classification of Diseases Version 10 (ICD-10) subheading, and specific comorbidities and symptoms defined using ICD-10 codes. Medications were reported by therapeutic class and defined using national drug codes.
A total of 587 patients with HD were matched to patients diagnosed with PD and GP controls, of which 453 (77%) had at least one HD ICD-10 code recorded in 2017. Major depressive disorders and other anxiety disorders were the most frequently reported disease subheadings in patients with HD (30.8% and 32.7% respectively); incidences were also higher in patients with PD (22.3%, 29.3%) than in GP (8.9%, 16.2%). Patients with HD used antidepressants and antipsychotics most (61.3% and 41.2% respectively), and at a higher frequency than in patients with PD (43.3%, 19.4%) and GP (25.4%, 8.5%).
This study provides insights into the most common comorbidities of, and medications used by, patients with HD, compared with PD and GP. Major depressive disorders and anxiety disorders are common to both HD and PD relative to the GP. Antidepressants and antipsychotics are commonly used in HD. Further studies exploring specific comorbidities and their relationship to medication use in these patient populations are ongoing.
Authors/Disclosures
Edward J. Wild, PhD, MBBS, MRCP (UCL Institute of Neurology)
PRESENTER
Dr. Wild has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Annexon Biosciences. Dr. Wild has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Dr. Wild has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Teitur Trophics. Dr. Wild has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Remix Therapeutics. Dr. Wild has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Hoffman La Roche. Dr. Wild has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Triplet Therapeutics. Dr. Wild has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vico Therapeutics. Dr. Wild has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Spark Therapeutics. Dr. Wild has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC Therapeutics. Dr. Wild has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for HDBuzz (a registered non-profit). The institution of Dr. Wild has received research support from CHDI Foundation (non-profit). The institution of Dr. Wild has received research support from Hoffman La Roche Ltd.
Lianna S. Ishihara, MPhil (University of Cambridge) No disclosure on file
David Oliveri David Oliveri has received personal compensation for serving as an employee of Genesis Research.